SU6668 is primarily utilized in the field of cancer research due to its ability to inhibit multiple receptor tyrosine kinases, which play a critical role in tumor growth and angiogenesis. It targets receptors such as VEGFR, PDGFR, and FGFR, making it a potential candidate for anti-cancer therapies. Researchers often use SU6668 in preclinical studies to evaluate its efficacy in suppressing tumor progression and disrupting blood vessel formation in various cancer models. Its application extends to understanding signaling pathways involved in cancer cell proliferation and survival, aiding in the development of targeted therapies. Additionally, SU6668 serves as a tool compound in pharmacological studies to explore the effects of multi-kinase inhibition on tumor microenvironments and metastasis.